Marc Lichtenfeld
Advisory Panelist
Healthcare & Biotech Expert
Marc Lichtenfeld is the Director of Research for Access Research Group; Senior Analyst for the Xcelerated Profits Report and a specialist in biotechnology/healthcare.
After starting out as a trader at Carlin Equities, Marc moved onto the contrarian Avalon Research Group as a Senior Analyst. He also obtained his NASD Series 86 & 87 licenses (required for all sell-side analysts). At Weiss Research, he co-managed the Real Wealth Portfolio and beat the S&P 500 by 17% over a six month period.
Marc joined the team following a successful spell as Senior Columnist at TheStreet.com. A contrarian investor by nature, Marc loves to shoot holes in conventional thinking and take profits where nobody else is looking. He’s broken several major stories on biotech companies and his investment approach blends thorough fundamental research with the timing tools of technical analysis.
He’s currently in the final stages of obtaining his Chartered Market Technician credential.
- What Investors Can Learn From the Recent Celebrity Outburst
- A New Wave of "Beatle Mania"... Four Ways to Profit From The Beatles: Rock Band
- Three Ways to Stop Making Emotional Investment Decisions
- How to Unearth Explosive Small-Cap HealthCare Stocks
- Recommended Investment Books: Nine Invaluable Resources For Every Investor